Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05629962 · ClinicalTrials.gov registry record · Phase 3
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
A Phase 3 study, sponsored by Atea Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,285
- Enrollment target
NCT05629962: Completed Phase 3 study, sponsored by Atea Pharmaceuticals.
NCT05629962 is a Phase 3 study that has completed, run by Atea Pharmaceuticals. The registered enrollment target is 2,285 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (196% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05629962, a Phase 3 study, has completed, sponsored by Atea Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,285 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching placebo orally for 5 days. Co-administration of locally available standard of care (SOC) is allowed. The total duration of the study is 60 days.
Interventions
- DRUG Placebo
- DRUG Bemnifosbuvir (BEM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,285 participants |
| Start Date | 2022-11-25 |
| Est. Completion | 2024-05-30 |
| Phase | Phase 3 |
What the finished NCT05629962 record still lists
NCT05629962 is an interventional study that assigns participants to a tested intervention. Its 2,285 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (196% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05629962 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05629962 about?
NCT05629962 is a clinical study titled "SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19". The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching place...
What is the current status of trial NCT05629962?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,285 participants. The study started on 2022-11-25. Estimated completion is 2024-05-30.
What interventions are being tested in trial NCT05629962?
The interventions under investigation include: Placebo (DRUG), Bemnifosbuvir (BEM) (DRUG).
Who is sponsoring clinical trial NCT05629962?
This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05629962's enrollment target sits among peer trials
2,285 94th of 2000 higher than 1,907 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05530343 · 2,298 participants · NA
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
- NCT04124120 · 2,300 participants · NA
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
- NCT05237258 · 2,300 participants · NA
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- NCT05732623 · 2,300 participants
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI